Protagonist Therapeutics (PTGX) Misses Q2 EPS by 3c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q2 EPS of ($0.68), $0.03 worse than the analyst estimate of ($0.65).

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Vail Resorts taps bankers for potential activist defense, Semafor reports
• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance